CHAPTER 1 METHODOLOGY AND SCOPE
1.1 MARKET SEGMENTATION AND SCOPE
1.2 REGIONAL SCOPE
1.2.1 SEGMENT DEFINITIONS
1.2.1.1 DRUG SEGMENT
1.2.1.2 APPLICATION SEGMENT
1.2.1.3 APPLICATION SEGMENT
1.2.1.4 END USE SEGMENT
1.3 ESTIMATES AND FORECAST TIMELINE
1.4 OBJECTIVES
1.4.1 OBJECTIVE - 1
1.4.2 OBJECTIVE - 2
1.4.3 OBJECTIVE - 3
1.5 RESEARCH METHODOLOGY
1.6 INFORMATION PROCUREMENT
1.6.1 PURCHASED DATABASE
1.6.2 GVR’S INTERNAL DATABASE
1.6.3 SECONDARY SOURCES
1.6.4 PRIMARY RESEARCH
1.7 INFORMATION OR DATA ANALYSIS
1.7.1 DATA ANALYSIS MODELS
1.8 MARKET FORMULATION & VALIDATION
1.9 MODEL DETAILS
1.9.1 COMMODITY FLOW ANALYSIS
1.10 RESEARCH ASSUMPTIONS
1.11 LIST OF SECONDARY SOURCES
CHAPTER 2 EXECUTIVE SUMMARY
2.1 MARKET SNAPSHOT
2.2 DRUG AND APPLICATION SEGMENT SNAPSHOT
2.3 END USE SEGMENT SNAPSHOT
2.4 COMPETITIVE LANDSCAPE SNAPSHOT
CHAPTER 3 INHALATION ANESTHESIA MARKET VARIABLES, TRENDS, AND SCOPE
3.1 MARKET LINEAGE OUTLOOK
3.1.1 PARENT MARKET OUTLOOK
3.1.2 RELATED/ANCILLARY MARKET OUTLOOK
3.2 MARKET DYNAMICS
3.2.1 MARKET DRIVER ANALYSIS
3.2.1.1 RISING SURGICAL PROCEDURES GLOBALLY
3.2.1.2 TECHNOLOGICAL ADVANCEMENTS IN ANESTHESIA DELIVERY SYSTEMS
3.2.1.3 GROWING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES
3.2.2 MARKET RESTRAINT ANALYSIS
3.2.2.1 ENVIRONMENTAL CONCERNS REGARDING ANESTHETIC GASES
3.2.2.2 ADVERSE EFFECTS ASSOCIATED WITH ANESTHESIA
3.3 BUSINESS ENVIRONMENT ANALYSIS
3.3.1 SWOT ANALYSIS; BY FACTOR (POLITICAL & LEGAL, ECONOMIC, SOCIAL, ENVIRONMENTAL, AND TECHNOLOGICAL)
3.3.2 PORTER’S FIVE FORCES ANALYSIS
CHAPTER 4 INHALATION ANESTHESIA MARKET - SEGMENT ANALYSIS, BY DRUG, 2025 - 2033
4.1 INHALATION ANESTHESIA MARKET: DRUG MOVEMENT ANALYSIS
4.2 INHALATION ANESTHESIA MARKET ESTIMATES & FORECAST, BY DRUG (USD MILLION)
4.2.1 SEVOFLURANE
4.2.2 CDESFLURANE
4.2.3 ISOFLURANE
4.2.4 OTHERS
CHAPTER 5 INHALATION ANESTHESIA MARKET - SEGMENT ANALYSIS, BY APPLICATION, 2025 - 2033
5.1 INHALATION ANESTHESIA MARKET: APPLICATION MOVEMENT ANALYSIS
5.2 INHALATION ANESTHESIA MARKET ESTIMATES & FORECAST, BY APPLICATION (USD MILLION)
5.2.1 INDUCTION
5.2.2 MAINTENANCE
CHAPTER 6 INHALATION ANESTHESIA MARKET - SEGMENT ANALYSIS, BY END USE, 2025 - 2033
6.1 INHALATION ANESTHESIA MARKET: END-USE MOVEMENT ANALYSIS
6.2 INHALATION ANESTHESIA MARKET ESTIMATES & FORECAST, BY END USE (USD MILLION)
6.2.1 GHOSPITALS
6.2.2 AMBULATORY SURGICAL CENTERS
6.2.2 OTHERS
CHAPTER 7 INHALATION ANESTHESIA MARKET - SEGMENT ANALYSIS, BY REGION, 2025 - 2033
7.1 INHALATION ANESTHESIA MARKET: REGIONAL OUTLOOK
7.2 NORTH AMERICA
7.2.1 NORTH AMERICA INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.2.2 U.S.
7.2.2.1 KEY COUNTRY DYNAMICS
7.2.2.2 U.S. INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.2.2.3 COMPETITIVE SCENARIO
7.2.2.4 REGULATORY FRAMEWORK
7.2.3 CANADA
7.2.3.1 KEY COUNTRY DYNAMICS
7.2.3.2 CANADA INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.2.3.3 COMPETITIVE SCENARIO
7.2.3.4 REGULATORY FRAMEWORK
7.3 EUROPE
7.3.1 EUROPE INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.3.2 UK
7.3.2.1 KEY COUNTRY DYNAMICS
7.3.2.2 UK INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.3.2.3 COMPETITIVE SCENARIO
7.3.2.4 REGULATORY FRAMEWORK
7.3.3 GERMANY
7.3.3.1 KEY COUNTRY DYNAMICS
7.3.3.2 GERMANY INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.3.3.3 COMPETITIVE SCENARIO
7.3.3.4 REGULATORY FRAMEWORK
7.3.4 FRANCE
7.3.4.1 KEY COUNTRY DYNAMICS
7.3.4.2 FRANCE INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.3.4.3 COMPETITIVE SCENARIO
7.3.4.4 REGULATORY FRAMEWORK
7.3.5 SPAIN
7.3.5.1 KEY COUNTRY DYNAMICS
7.3.5.2 SPAIN INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.3.5.3 COMPETITIVE SCENARIO
7.3.5.4 REGULATORY FRAMEWORK
7.3.6 ITALY
7.3.6.1 KEY COUNTRY DYNAMICS
7.3.6.2 ITALY INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.3.6.3 COMPETITIVE SCENARIO
7.3.6.4 REGULATORY FRAMEWORK
7.3.7 DENMARK
7.3.7.1 KEY COUNTRY DYNAMICS
7.3.7.2 DENMARK INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.3.7.3 COMPETITIVE SCENARIO
7.3.7.4 REGULATORY FRAMEWORK
7.3.8 SWEDEN
7.3.8.1 KEY COUNTRY DYNAMICS
7.3.8.2 SWEDEN INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.3.8.3 COMPETITIVE SCENARIO
7.3.8.4 REGULATORY FRAMEWORK
7.3.9 NORWAY
7.3.9.1 KEY COUNTRY DYNAMICS
7.3.9.2 NORWAY INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.3.9.3 COMPETITIVE SCENARIO
7.3.9.4 REGULATORY FRAMEWORK
7.3.10 REST OF EUROPE INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.4 ASIA PACIFIC
7.4.1 ASIA PACIFIC INHALATION ANESTHESIA MARKET ESTIMATED AND FORECASTS, 2025 - 2033
7.4.2 JAPAN
7.4.2.1 KEY COUNTRY DYNAMICS
7.4.2.2 JAPAN INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.4.2.3 COMPETITIVE SCENARIO
7.4.2.4 REGULATORY FRAMEWORK
7.4.3 CHINA
7.4.3.1 KEY COUNTRY DYNAMICS
7.4.3.2 CHINA INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.4.3.3 COMPETITIVE SCENARIO
7.4.3.4 REGULATORY FRAMEWORK
7.4.4 INDIA
7.4.4.1 KEY COUNTRY DYNAMICS
7.4.4.2 INDIA INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.4.4.3 COMPETITIVE SCENARIO
7.4.4.4 REGULATORY FRAMEWORK
7.4.5 AUSTRALIA
7.4.5.1 KEY COUNTRY DYNAMICS
7.4.5.2 AUSTRALIA INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.4.5.3 COMPETITIVE SCENARIO
7.4.5.4 REGULATORY FRAMEWORK
7.4.6 THAILAND
7.4.6.1 KEY COUNTRY DYNAMICS
7.4.6.2 THAILAND INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.4.6.3 COMPETITIVE SCENARIO
7.4.6.4 REGULATORY FRAMEWORK
7.4.7 SOUTH KOREA
7.4.7.1 KEY COUNTRY DYNAMICS
7.4.7.2 SOUTH KOREA INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.4.7.3 COMPETITIVE SCENARIO
7.4.7.4 REGULATORY FRAMEWORK
7.4.8 REST OF ASIA PACIFIC INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.5 LATIN AMERICA
7.5.1 LATIN AMERICA INHALATION ANESTHESIA MARKET ESTIMATED AND FORECASTS, 2025 - 2033
7.5.2 BRAZIL
7.5.2.1 KEY COUNTRY DYNAMICS
7.5.2.2 BRAZIL INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.5.2.3 COMPETITIVE SCENARIO
7.5.2.4 REGULATORY FRAMEWORK
7.5.3 MEXICO
7.5.3.1 KEY COUNTRY DYNAMICS
7.5.3.2 MEXICO INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.5.3.3 COMPETITIVE SCENARIO
7.5.3.4 REGULATORY FRAMEWORK
7.5.4 ARGENTINA
7.5.4.1 KEY COUNTRY DYNAMICS
7.5.4.2 ARGENTINA INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.5.4.3 COMPETITIVE SCENARIO
7.5.4.4 REGULATORY FRAMEWORK
7.5.5 REST OF LATIN AMERICA INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.6 MIDDLE EAST AND AFRICA
7.6.1 MIDDLE EAST AND AFRICA INHALATION ANESTHESIA MARKET ESTIMATED AND FORECASTS, 2025 - 2033
7.6.2 SOUTH AFRICA
7.6.2.1 KEY COUNTRY DYNAMICS
7.6.2.2 SOUTH AFRICA INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.6.2.3 COMPETITIVE SCENARIO
7.6.2.4 REGULATORY FRAMEWORK
7.6.3 SAUDI ARABIA
7.6.3.1 KEY COUNTRY DYNAMICS
7.6.3.2 SAUDI ARABIA INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.6.3.3 COMPETITIVE SCENARIO
7.6.3.4 REGULATORY FRAMEWORK
7.6.4 UAE
7.6.4.1 KEY COUNTRY DYNAMICS
7.6.4.2 UAE INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.6.4.3 COMPETITIVE SCENARIO
7.6.4.4 REGULATORY FRAMEWORK
7.6.5 KUWAIT
7.6.5.1 KEY COUNTRY DYNAMICS
7.6.5.2 KUWAIT INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
7.6.5.3 COMPETITIVE SCENARIO
7.6.5.4 REGULATORY FRAMEWORK
7.6.6 REST OF MEA INHALATION ANESTHESIA MARKET ESTIMATES AND FORECASTS, 2025 - 2033
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. COMPANY CATEGORIZATION
8.2. STRATEGY MAPPING
8.2.1. NEW PRODUCT LAUNCH
8.2.2. PARTNERSHIPS
8.2.3. ACQUISITION
8.2.4. COLLABORATION
8.2.5. FUNDING
8.3. KEY COMPANY MARKET SHARE ANALYSIS, 2024
8.4. COMPANY HEAT MAP ANALYSIS
8.5. COMPANY PROFILES
8.5.1. ABBVIE, INC.
8.5.1.1. COMPANY OVERVIEW
8.5.1.2. FINANCIAL PERFORMANCE
8.5.1.3. PRODUCT BENCHMARKING
8.5.1.4. STRATEGIC INITIATIVES
8.5.2. BAXTER INTERNATIONAL
8.5.2.1. COMPANY OVERVIEW
8.5.2.2. FINANCIAL PERFORMANCE
8.5.2.3. PRODUCT BENCHMARKING
8.5.2.4. STRATEGIC INITIATIVES
8.5.3. FRESENIUS SE & CO.
8.5.3.1. COMPANY OVERVIEW
8.5.3.2. FINANCIAL PERFORMANCE
8.5.3.3. PRODUCT BENCHMARKING
8.5.3.4. STRATEGIC INITIATIVES
8.5.4. HALOCARBON PRODUCTS CORPORATION
8.5.4.1. COMPANY OVERVIEW
8.5.4.2. FINANCIAL PERFORMANCE
8.5.4.3. PRODUCT BENCHMARKING
8.5.4.4. STRATEGIC INITIATIVES
8.5.5. HIKMA PHARMACEUTICALS
8.5.5.1. COMPANY OVERVIEW
8.5.5.2. FINANCIAL PERFORMANCE
8.5.5.3. PRODUCT BENCHMARKING
8.5.5.4. STRATEGIC INITIATIVES
8.5.6. KENT SCIENTIFIC CORPORATION
8.5.6.1. COMPANY OVERVIEW
8.5.6.2. FINANCIAL PERFORMANCE
8.5.6.3. PRODUCT BENCHMARKING
8.5.6.4. STRATEGIC INITIATIVES
8.5.7. MIDMARK CORPORATION
8.5.7.1. COMPANY OVERVIEW
8.5.7.2. FINANCIAL PERFORMANCE
8.5.7.3. PRODUCT BENCHMARKING
8.5.7.4. STRATEGIC INITIATIVES
8.5.8. NOVARTIS AG
8.5.9. NYSORA
8.5.10. PIRAMAL PHARMA LTD.
8.5.11. SANDOZ INTERNATIONAL
8.5.12. SEDANA MEDICAL AB
8.5.13. VERO BIOTECH
8.5.14. OTHERS
CHAPTER 9 CONCLUSION
著作権 ©2022 無断複写・転載を禁じます
